Teva Pharmaceutical Industries (TEVA) Land & Improvements (2012 - 2018)
Teva Pharmaceutical Industries' (TEVA) quarterly Land & Improvements came in at $351.0 million in Q4 2018, down 10.0% YoY from $390.0 million in Q4 2017, and down 2.77% on a QoQ basis from $361.0 million in Q3 2018.
Teva Pharmaceutical Industries (TEVA) Land & Improvements (2012 - 2018) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 7 years of Land & Improvements data on file, last reported at $351.0 million in Q4 2018.
- Quarterly Land & Improvements fell 10.0% year-over-year to $351.0 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $351.0 million (down 10.0% YoY) and the FY2018 annual result came in at $351.0 million, down 10.0% from the prior year.
- Land & Improvements eased to $351.0 million in Q4 2018, from $361.0 million in the prior quarter.
- In the past five years, Land & Improvements ranged from a high of $459.0 million in Q3 2016 to a low of $351.0 million in Q4 2018.
- A 5-year average of $399.7 million and a median of $391.5 million in 2017 frame the typical range for Land & Improvements.
- Annual changes were most pronounced in 2016 — Land & Improvements grew 11.42% — and 2018, when it dropped 20.44%.
- Tracing TEVA's Land & Improvements over 5 years: stood at $372.0 million in 2014, then increased by 5.91% to $394.0 million in 2015, then climbed by 11.42% to $439.0 million in 2016, then declined by 11.16% to $390.0 million in 2017, then declined by 10.0% to $351.0 million in 2018.
- The last three Land & Improvements figures came in at $351.0 million (Q4 2018), $361.0 million (Q3 2018), and $374.0 million (Q2 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 351.00 Mn |
| Sep 30, 2018 | 361.00 Mn |
| Jun 30, 2018 | 374.00 Mn |
| Mar 31, 2018 | 358.00 Mn |
| Dec 31, 2017 | 390.00 Mn |
| Sep 30, 2017 | 393.00 Mn |
| Jun 30, 2017 | 455.00 Mn |
| Mar 31, 2017 | 450.00 Mn |
| Dec 31, 2016 | 439.00 Mn |
| Sep 30, 2016 | 459.00 Mn |
| Dec 31, 2015 | 394.00 Mn |
| Dec 31, 2014 | 372.00 Mn |
| Dec 31, 2013 | 446.00 Mn |
| Dec 31, 2012 | 475.00 Mn |